Gufic Biosciences (BOM:509079) Beneish M-Score: -2.15 (As of Jun. 28, 2026)


BOM:509079 Gufic Biosciences Ltd BOM:509079
73 GF Score
Price ₹360.15
GF Value ₹407.00
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Gufic Biosciences Beneish M-Score?

Gufic Biosciences BOM:509079 -2.09% 73 Beneish M-Score is -2.15 as of Jun. 28, 2026. GuruFocus rates BOM:509079 with a GF Score™ of 73/100 and a GF Value™ of ₹407.00 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 908 Drug Manufacturers companies, Gufic Biosciences ranks worse than 73.35% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.15 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Gufic Biosciences's Beneish M-Score or its related term are showing as below:

BOM:509079' s Beneish M-Score Range Over the Past 10 Years
Min: -2.83   Med: -2.05   Max: -1.56
Current: -2.15

During the past 13 years, the highest Beneish M-Score of Gufic Biosciences was -1.56. The lowest was -2.83. And the median was -2.05.


Gufic Biosciences Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Gufic Biosciences's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gufic Biosciences Beneish M-Score Chart

Gufic Biosciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.56 -1.72 -1.71 -2.79 -2.15

Gufic Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.79 0.00 0.00 0.00 -2.15

BOM:509079 vs ZTS: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Gufic Biosciences's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gufic Biosciences Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gufic Biosciences's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Gufic Biosciences's Beneish M-Score falls into.


BOM:509079
73GF Score
Gufic Biosciences Ltd BOM:509079
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gufic Biosciences Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Gufic Biosciences for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.8219+0.528 * 0.9803+0.404 * 1.4381+0.892 * 1.1515+0.115 * 0.6733
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0+4.679 * 0.014338-0.327 * 1.0325
=-2.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was ₹2,981 Mil.
Revenue was ₹9,440 Mil.
Gross Profit was ₹5,228 Mil.
Total Current Assets was ₹8,021 Mil.
Total Assets was ₹13,424 Mil.
Property, Plant and Equipment(Net PPE) was ₹5,070 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹308 Mil.
Selling, General, & Admin. Expense(SGA) was ₹0 Mil.
Total Current Liabilities was ₹5,178 Mil.
Long-Term Debt & Capital Lease Obligation was ₹1,194 Mil.
Net Income was ₹642 Mil.
Gross Profit was ₹0 Mil.
Cash Flow from Operations was ₹450 Mil.
Total Receivables was ₹3,149 Mil.
Revenue was ₹8,198 Mil.
Gross Profit was ₹4,451 Mil.
Total Current Assets was ₹6,245 Mil.
Total Assets was ₹11,694 Mil.
Property, Plant and Equipment(Net PPE) was ₹5,247 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹211 Mil.
Selling, General, & Admin. Expense(SGA) was ₹262 Mil.
Total Current Liabilities was ₹3,876 Mil.
Long-Term Debt & Capital Lease Obligation was ₹1,501 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(2980.581 / 9440.066) / (3149.29 / 8198.059)
=0.315737 / 0.384151
=0.8219

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(4451.048 / 8198.059) / (5228.264 / 9440.066)
=0.542939 / 0.553838
=0.9803

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (8021.153 + 5069.972) / 13423.74) / (1 - (6245.225 + 5246.931) / 11693.637)
=0.024778 / 0.01723
=1.4381

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=9440.066 / 8198.059
=1.1515

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(210.646 / (210.646 + 5246.931)) / (308.326 / (308.326 + 5069.972))
=0.038597 / 0.057328
=0.6733

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(0 / 9440.066) / (262.384 / 8198.059)
=0 / 0.032006
=0

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((1194.085 + 5178.49) / 13423.74) / ((1500.929 + 3875.572) / 11693.637)
=0.474724 / 0.45978
=1.0325

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(642.147 - 0 - 449.678) / 13423.74
=0.014338

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Gufic Biosciences has a M-score of -2.15 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.15 mean?
Gufic Biosciences (BOM:509079) has a Beneish M-Score of -2.15 as of Jun. 28, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Gufic Biosciences and its competitors. According to the industry distribution chart, Gufic Biosciences ranks #666 out of 908 companies in the Drug Manufacturers industry, placing it in the top 73.3%.
Is Gufic Biosciences' Beneish M-Score too high?
Gufic Biosciences' current Beneish M-Score is -2.15. Based on the distribution chart, Gufic Biosciences ranks #666 out of 908 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Gufic Biosciences has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gufic Biosciences' Beneish M-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Gufic Biosciences ranks #666 out of 908 companies for Beneish M-Score. This places Gufic Biosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Gufic Biosciences and its competitors. Gufic Biosciences's current Beneish M-Score is -2.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gufic Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Gufic Biosciences (BOM:509079) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹407.00, compared to a current price of ₹360.15 — trading 11.5% below its estimated fair value. The current Beneish M-Score is -2.15. Gufic Biosciences' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Gufic Biosciences (BOM:509079), the current Beneish M-Score is -2.15 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gufic Biosciences (BOM:509079) Overvalued in 2026?

Based on GuruFocus' analysis, Gufic Biosciences stock appears to be undervalued. The current stock price of ₹360.15 is trading 11.5% below its estimated GF Value™ of ₹407.00. GuruFocus considers Gufic Biosciences to be Modestly Undervalued.

Key valuation signals for BOM:509079:

  • Beneish M-Score: -2.15
  • GF Value™: ₹407.00 vs. price of ₹360.15 (11.5% below fair value)
  • GF Score™: 73/100 with 6 warning signs

No single metric tells the full story. See the BOM:509079 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Gufic Biosciences Business Description

Other Exchanges GUFICBIO:India
Address SM House, 11 Sahakar Road, 1st to 4th Floor, Vile Parle (East), Mumbai, MH, IND, 400 057
Gufic Biosciences Ltd is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Geographically, it derives a majority of revenue from India. Its product portfolio includes Criticare, Criticare Life, Ferticare, Spark, Herbal, and other products. The company's lyophilized product includes antibiotics, anti-fungal, cardiac, infertility, anti-viral, and a proton-pump inhibitor. It derives maximum revenue from India.
73GF Score

Get the complete analysis for BOM:509079

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹360.15
Price
₹407.00
GF Value